Topics:

Xcytrin Is Well Tolerated in Glioblastoma and Glioma Trials

Xcytrin Is Well Tolerated in Glioblastoma and Glioma Trials

SAN FRANCISCO—Motexafin gadolinium (Xcytrin), an experimental drug
that makes brain tumors more sensitive to radiation, appears to be well
tolerated in adults with primary glioblastoma multiforme and children with
gliomas, according to preliminary results from two phase I trials presented at
the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Judith M. Ford, MD, PhD, assistant professor of radiation oncology, UCLA
Medical Center, said that median survival for the first 24 patients in the
glioblastoma study was 17.3 months (abstract 213). She also reported that
imaging studies showed the drug to be present in the tumor throughout the
course of treatment, but not in normal brain tissue.

Xcytrin is the first of a new class of porphyrin-like compounds called
texaphyrins that are active as reduction oxidation (redox) modulators. The
agent enhances radiation-induced apoptosis through caspase activation secondary
to futile redox cycling.

Markus Renschler, MD, vice president of oncology clinical development for
Xcytrin-developer Pharmacyclics, Inc., Sunnyvale, Calif (www.pcyc.com), said
the company is proceeding with a phase II glioblastoma trial in the hope of
starting a phase III trial by early next year.

Dr. Renschler told ONI that the 17.3 months median survival in the phase I
study of patients with advanced glioblastoma was "provocative," since
survival for these patients as reported in the literature is generally only 10
to 11 months.

Pediatric Trial

Response and survival data for the pediatric study of intrinsic pontine
(brainstem) gliomas are blocked until completion under the Children’s
Oncology Group protocol, said Minesh Mehta, MD, of the University of Wisconsin
Medical School, Madison.

He reported (abstract 243) that the trial has established that children can
take Xcytrin on a 5-day-a-week dosing schedule. Sixteen children had
participated in the dose-escalation trial as of May, with the fourth cohort
receiving 1.9 mg/m² five times a week. A fifth cohort at 2.1 mg/m² was expected
to start shortly.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.